Rapid monoclonal antibody generation via dendritic cell targeting in vivo

Hybridoma and Hybridomics

Volumn 22, Issue 1, 2003, Pages 23-31

  Berry, Jody D ^a   Licea, Alexei ^a,b   Popkov, Mikhail ^a   Cortez, Xochitl ^b   Fuller, Roberta ^a   Elia, Marikka ^a   Kerwin, Lisa ^a   Kubitz, Diane ^a   Barbas III, Carlos F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b CENTRO DE INVESTIGACIÓN CIENTÍFICA Y DE EDUCACIÓN SUPERIOR DE ENSENADA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 3; LECTIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TARGET CELL;

ANIMALIA; CRICETINAE; MURINAE;

EID: 0037312355     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685903321538053     Document Type: Article

References (42)

1. Ada GL, and Ramsay AJ: Vaccines, vaccination and the immune response. Lippincott-Raven, New York, 1986.
2. Francis MJ, Hastings GZ, Syred AD, McGinn B, Brown F, and Rowlands DJ: Nonresponsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature 1987;330:168-170.
3. Del Giudice G, Cooper JA, Merino J, Verdini AS, Pessi A, Togna AR, Engers HD, Corradin G, and Lambert PH: The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is A-Ab-restricted: possible implications for malaria vaccines. J Immunol 1986;137: 2952-2960.
4. Cox J, Ivanyi J, Young D, Lamb J, Syred J, and Francis M: Orientation of epitopes influences the immunogenicity of synthetic peptide dimers. Eur J Immunol 1988;18:2015-2019.
5. Fernandez IM, Snijders A, Benaissa-Trouw B, Harmsen M, Snippe H, and Kraaijveld CA: Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against semiliki forest virus. J Virol 1993;67:5843-5848.
6. Zhong G, Smith GP, Berry J, and Brunham RC: Conformational mimicry of a chlamydial neutralization epitope on filamentous phage. J Biol Chem 1994;269:24183-24188.
7. Bastien N, Trudel M, and Simard C: Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccine. Vaccine 1999;17:832-836.
8. Tam JP: Recent advances in multiple antigen peptides. J Immunol Methods 1996;196:17-32.
9. Barber BH: The immunotargeting approach to adjuvant-independent subunit vaccine design. Semin Immunol 1997;9:293-301.
10. Carayanniotis G, and Barber B: Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature 1987;327:59-61.
11. Lees A, Morris S, Thyphronitis G, Holmes J, Inman J, and Finkelman FD: Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J Immunol 1990;145:3594-3600.
12. Squire CM, Studer EJ, Lees A, Finkelman FD, and Conrad DH: Antigen presentation is enhanced by targeting antigen to the Fc epsilon RII by antigen-anti-Fc epsilon RII conjugates. J Immunol 1994;152:4388-4396.
13. Keler T, Guyre P, Vitale L, Sundarapandiyan K, van de Winkel J, Deo Y, and Graziano RF: Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol 2000;165:6738-6742.
14. Carayanniotis G, Skea D, Luscher M, and Barber B: Adjuvant-independent immunization by immunotargeting antigens to MHC and non-MHC determinants in vivo. Mol Immunol 1991;3:261-267.
15. Wang H, Griffiths M, Burton D, and Ghazel P: Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA 2000;96:847-852.
16. Emini E, Jameson B, and Wimmer E: Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature 1983;304:699-703.
17. Sutcliffe A, Shinnick T, Green N, and Lerner RA: Antibodies that react with predetermined sites on proteins. Science 1983;219: 660-666.
18. Nayak B, Tuteja R, Manivel V, Roy R, Vishwakarma R, and Rao K: B cell responses to a peptide epitope. V. Kinetic regulation of repertoire discrimination and antibody optimization for epitope. J Immunol 1998;161:3510-3519.
19. Bachmann MF, Kalinke U, Althage A, Freer G, Brukhart C, Roost H-P, Aguet M, Hengartner H, and Zinkernagel RM: The role of antibody concentration and avidity in antiviral protection. Science 1997;276:2024-2027.
20. Skea D, and Barber B: Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, isotype distribution, and induction of long term memory. J Immunol 1993;151:3557-3568.
21. Berg S, Mjaaland S, and Fossum S: Comparing macrophages and dendritic leukocytes as antigen-presenting cells for humoral responses in vivo by antigen targeting. Eur J Immunol 1994;24: 1262-1268.
22. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, and van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
23. Curtis BM, Scharnowske S, and Watson AJ: Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci USA 1992;89:8356-8360.
24. Soilleux EJ, Barten R, and Trowsdale J: DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J Immunol 2000; 165:2937-2942.
25. Lane RD: A short-duration polyethylene glycol fusion technique for increasing production of monoclonal antibody-secreting hybridomas. J Immunol Methods 1985;81:223-228.
26. Soilleux EJ, Morris LS, Leslie G, Chehimi J, Luo Q, Levroney E, Trowsdale J, Montaner LJ, Doms RW, Weissman D, Coleman N, and Lee B: Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukocyte Biol 2002;71:445-457.
27. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, and Figdor CG: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000;100:575-585.
28. Pohlmann S, Soilleux EJ, Baribaud F, Leslie GJ, Morris LS, Trowsdale J, Lee B, Coleman N, and Doms RW: DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci USA 2001;98:2670-2675.
29. Davis JM, Pennington JE, Kubler AM, and Conscience JF: A simple, single-step technique for selecting and cloning hybridomas for the production of monoclonal antibodies. J Immunol Methods 1982;50:161-171.
30. Wagner SD, Popov AV, Davies SL, Xian J, Neuberger MS, and Brüggemann M: The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci. Eur J Immunol 1994;24:2672-2681.
31. Jakobovits A: Production of fully human antibodies by transgenic mice. Curr Opin Biotechnol 1995;6:561-566.
32. Ishida I, Yoshida H, and Tomizuka K: Production of a diverse repertoire of human antibodies in genetically engineered mice. Microbiol Immunol 1998;42:143-150.
33. Metlay J, Witmer-Pack M, Agger R, Crowley M, Lawless D, and Steinman R: The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med 1990;171:1753-1771.
34. Roost H, Bachmann M, Haag A, Kalinke U, Pliska V, Hengartner H, and Zinkernagel RM: Early high-affinity neutralizing anti-viral IgG responses without further overall improvement of affinity. Proc Natl Acad Sci USA 1995;92:1257-1261.
35. Kalinke U, Bucher EM, Ernst B, Oxenius A, Roost H, Geley S, Kofler R, Zinkernagel RM, and Hengartner H: The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity 1996;5: 639-652.
36. Andria M, Levy S, and Benjamini E: Diverse VH and V1 genes are used to produce antibodies against a defined protein epitope. J Immunol 1990;144:2614-2619.
37. Manser T: Mitogen driven B cell proliferation and differentiation are not accompanied by hypermutation of immunoglobulin variable region genes. J Immunol 1987;139:234-238.
38. Wykes M, and MacPherson G: Dendritic cell-B-cell interaction: dendritic cells provide B cells with CD40-independent proliferation signals and CD40-dependent survival signals. Immunology 2000;100:1-3.
39. Ludewig B, Barchiesi F, Pericin M, Zinkernagel RM, Hengartner H, and Schwendener RA: In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 2000;19:23-32.
40. Shaw D, Stanley C, Partidos C, and Steward M: Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after coimmunization. Mol Immunol 1993;30:961-968.
41. Partidos CD, Beignon AS, Semetey V, Briand JP, and Muller S: The bare skin and the nose as non-invasive routes for administration of peptide vaccines. Vaccine 2001;19:2708-2715.
42. Van Regenmortel MH: Pitfalls of reductionism in the design of peptide based-vaccines. Vaccine 2001;19:2369-2374.